More Press Releases

View Older Stories View Newer Stories

Dec 6, 2025 04:00PM TheOther Debuts Premium Matcha at an Intimate Art Basel Celebration in Miami Co-Hosted By Central Cee
Dec 6, 2025 03:38PM Lustock: A Modern Trading Hub Built for Professional and Retail Investors
Dec 6, 2025 03:40PM Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
Dec 6, 2025 10:31AM From Studio to Catwalk: Music Inspires Dime City Apparel’s Designs
Dec 6, 2025 03:30PM Best Place to Buy Rugs (2025): Rugs Direct Recognized for Quality, Selection and Style by Expert Consumers
Dec 6, 2025 03:30PM BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Dec 6, 2025 03:03PM Strength-Based ADHD Testing for Teens and Adults Who Were Never Diagnosed: Validation, Understanding, and New Possibilities
Dec 6, 2025 03:00PM Best HR and Payroll Software (2025): QuickBooks Awarded for Accuracy and Team Management by Better Business Advice
Dec 6, 2025 02:17PM Raythink Ranks 9th in 2025 a&s Security 50, Showcasing AI-Driven Thermal Imaging & Security Solutions
Dec 6, 2025 05:05PM XRP Price Today: Is Remittix the Reason Other Cryptos Price Isn’t Increasing Despite Expansion?
Dec 6, 2025 05:04PM Is Dogecoin Price Attainable? Analysts Pick 3 Sub Tokens Likely to Lead The Charge
Dec 6, 2025 02:10PM New to The Street Broadcasts Tonight on Bloomberg at 6:30 PM EST Featuring Roadzen, BioVie, and TY J Young Wealth
Dec 6, 2025 05:03PM Bitcoin Outlook for 2026: Can BTC Bounce Back in 2026? AI Predicts Remittix To Grow
Dec 6, 2025 02:01PM Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
Dec 6, 2025 02:01PM Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
Dec 6, 2025 02:00PM Hep B Free - Calls for Continued Universal Hepatitis B Birth-Dose Vaccination Despite Federal Advisory Shift
Dec 6, 2025 02:00PM Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
Dec 6, 2025 02:00PM Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Dec 6, 2025 02:00PM Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Dec 6, 2025 02:00PM Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Dec 6, 2025 02:00PM Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Dec 6, 2025 01:51PM THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
Dec 6, 2025 01:44PM Copper Property CTL Pass Through Trust Issues Monthly Reporting Package for November 2025
Dec 6, 2025 01:15PM Mudcup 2025 (The Eighth Edition) Was A Smashing Success!
Dec 6, 2025 12:57PM GJK Facilities Announces Scholarship to Support Aspiring Aerospace Engineer
Dec 6, 2025 12:50PM Elysium Wealth Advisors Expands Services for Expatriates Across Europe
Dec 6, 2025 12:45PM AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio
Dec 6, 2025 12:39PM BexBack Launches $100 Welcome Bonus and 100% Deposit Match as It Expands 100x Crypto Futures Trading Program
Dec 6, 2025 12:37PM Roofing Expert Keith Miller Clarifies Why Flashing Is the Source of Many Roof Leaks in HelloNation
Dec 6, 2025 12:25PM Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Dec 6, 2025 12:17PM Worthington Steel Issues Statement Regarding Klöckner & Co SE
Dec 6, 2025 12:00PM RadiantVibe Capital Consortium Debuts Insight Access Dashboard as Part of Ambrose Wetherby’s Transparency Initiative
Dec 6, 2025 11:01AM Watchung Hardscaping & Erosion Control: Retaining Wall Installations Announced
Dec 6, 2025 11:27AM Mutuum Finance Completes Lending and Borrowing Smart Contracts Ahead of Security Review
Dec 6, 2025 02:20PM Is Digitap ($TAP) Crypto Presale the Next Momentum Play?
Dec 6, 2025 11:24AM Anthony Constantino’s ‘Thank You President Trump’ Album Release To Light Up Fontainebleau LIV Tonight; Hit song “Fight” has over 4 million views in 5 days
Dec 6, 2025 01:58PM Digitap ($TAP) Volume Explodes in Final 24 Hours of Cyber Monday Sale
Dec 6, 2025 11:00AM LiberNovo Goes Global: New Markets & A Vision for Healthy Workspaces
Dec 6, 2025 11:00AM Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Dec 6, 2025 10:30AM Ascent Solutions Appoints Previous Microsoft Sales Leader Jeff Mutschler as Senior Vice President of Alliances
Dec 6, 2025 10:15AM Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
Dec 6, 2025 10:05AM Lordsbook Launches Its New App & Is Leading The Way To Christian Community & Discipleship
Dec 6, 2025 10:00AM When to Choose Veneers vs. Partial Dentures
Dec 6, 2025 10:00AM JCBC Publishing, LLC Announces Launch of 'That Kind of Girl,' Jacey Bici's Debut Novel, in 2025
Dec 6, 2025 10:00AM JCBC Publishing, LLC Announces Launch of 'That Kind of Girl,' Jacey Bici's Debut Novel, in 2025
Dec 6, 2025 09:45AM Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
Dec 6, 2025 09:25AM Midwest MSP Titans of the Industry Recognizes GoTech IT Solutions as 2025 Awards Finalist
Dec 6, 2025 09:30AM Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Dec 6, 2025 09:30AM Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Dec 6, 2025 09:30AM Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at
View Newer Stories View Older Stories